Thomas Slavin, MD, FACMG, DABCC, Discusses the Use of the myChoice CDx for Ovarian Cancer

September 11, 2020

New guidelines published by the American Society for Clinical Oncology (ASCO) on the use of PARP inhibitors in the management of ovarian cancer included the myChoice CDx as the sole companion diagnostic to be used in this space.

New guidelines published by the American Society for Clinical Oncology (ASCO) detail recommendations on the use of PARP inhibitors in the management of ovarian cancer.

“The purpose of this guideline is to provide clinicians, other health care practitioners, patients, and caregivers with recommendations regarding the role of [PARP inhibitors] in the management of [epithelial ovarian, tubal, or primary peritoneal cancer; EOC] based on the best available evidence,” the authors of the guidelines wrote.

Notably, the guidelines specifically cite the myChoice CDx as the sole companion diagnostic to be used in this space. Further, the myChoice CDx was recommended for use in both newly diagnosed and recurrent ovarian cancer.

In an interview with CancerNetwork®, Thomas Slavin, MD, FACMG, DABCC, senior vice president of Medical Affairs for Myriad Oncology, the developer of the diagnostic, spoke about the inclusion of the myChoice CDx in the recommendations and what the diagnostic tool offers for this patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer [news release]. Salt Lake City. Published August 21, 2020. Accessed September 11, 2020. https://finance.yahoo.com/news/american-society-clinical-oncology-exclusively-110500791.html